Quest Diagnostics

Report Status: Final

Patient Information	Specimen Information	Client Information

COMMENTS:

Test Name	In Range	Out Of Range	Reference Range	Lab
ALPHA GAL PANEL				
GALACTOSE ALPHA 1,3				
GALACTOSE IGE	<0.10		<0.10 kU/L	

Results above 0.1 kU/L indicate an allergen-specific IgE sensitization to galactose-a-1,3-galactose, and such patients are at risk for delayed allergic reactions following beef, pork, or lamb consumption. Circulating IgE antibodies may remain undetectable despite a convincing clinical history because these antibodies may be directed towards allergens revealed or altered during industrial processing, cooking, or digestion and therefore do not exist in the original food for which the patient is tested. Sometimes individuals diagnosed with chronic urticaria may develop IgE antibodies directed against human thyroglobulin. Such antibodies may cross-react with the bovine thyroglobulin used in ImmunoCAP(R) Allergen o215, alpha-Gal, leading to a false-positive test result. A definitive diagnosis should be based on the evaluation of both clinical and laboratory findings and not on any single diagnostic method. Additional information can be found at http://www.phadia.com

PERFORMING SITE:

SPECIMEN:

Quest Diagnostics

Report Status: Final

Patient Information	Specimen Information	Client Information

ALLERGEN REPORT

ALPHA GAL PANEL		CLASS
Performing Lab:		0 1 2 3 4 5 6
Test Name	**Results kU/L**	
BEEF (F27) IGE	<0.10	
LAMB (F88) IGE	<0.10	

ALPHA GAL PANEL		CLASS
Performing Lab:		0 1 2 3 4 5 6
Test Name	**Results kU/L**	
PORK (F26) IGE	<0.10	

INTERPRETATION

Performing Lab:

See Endnote 1

Endnote 1

Specific IGE Class	kU/L	Level of Allergen Specific IGE Antibody
0	<0.10	Absent/Undetectable
0/1	0.10-0.34	Very Low Level
1	0.35-0.69	Low Level
2	0.70-3.49	Moderate Level
3	3.50-17.4	High Level
4	17.5-49.9	Very High Level
5	50-100	Very High Level
6	>100	Very High Level

The clinical relevance of allergen results of 0.10-0.34 kU/L are undetermined and intended for specialist use.

Allergens denoted with a "**" include results using one or more analyte specific reagents. In those cases, the test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by the U.S. Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

PERFORMING SITE:

SPECIMEN: